Arcus and Summit Partner on Kidney Cancer Combination Therapy Trial
Event summary
- Arcus Biosciences and Summit Therapeutics will collaborate on a clinical trial to evaluate the combination of casdatifan (HIF-2α inhibitor) and ivonescimab (PD-1/VEGF bispecific antibody) in clear cell renal cell carcinoma (ccRCC).
- The study will be added as a new cohort to Arcus’s ARC-20 platform trial, with initial data expected by mid-2027.
- Summit will supply ivonescimab, while Arcus will conduct and sponsor the combination study; both companies will share study costs and retain commercial rights to their respective molecules.
The big picture
This partnership aligns with a broader industry trend of developing targeted combination therapies for oncology, particularly in areas like ccRCC where survival rates remain low. The collaboration could position both Arcus and Summit as key players in the evolving renal cell carcinoma treatment space, especially if the trial yields positive results.
What we're watching
- Clinical Efficacy
- Whether the combination of casdatifan and ivonescimab demonstrates superior safety and efficacy compared to existing treatments for ccRCC.
- Regulatory Pathway
- The pace at which Arcus and Summit can advance this combination through clinical trials and potentially secure regulatory approvals.
- Commercial Strategy
- How the companies plan to leverage this collaboration to strengthen their positions in the kidney cancer treatment landscape.